Video
Dr. Aggarwal the Significance of the IMpower010 Trial in PD-L1+ NSCLC
Author(s):
Charu Aggarwal, MD, MPH, discusses the significance of the phase 3 IMpower010 trial in patients with PD-L1–positive non–small cell lung cancer.
Charu Aggarwal, MD, MPH, Leslye M. Heisler Associate Professor for Lung Cancer Excellence, Perelman School of Medicine of the University of Pennsylvania, physician, physician leader, Airways Malignancies, Abramson Cancer Center, Penn Medicine, discusses the significance of the phase 3 IMpower010 trial (NCT02486718) in patients with PD-L1–positive non–small cell lung cancer (NSCLC).
The results of the IMpower010 trial showed that the median disease-free survival was not reached with adjuvant atezolizumab (Tecentriq) compared with 35.3 months with best supportive care in patients with PD-L1–positive, stage II through IIIA NSCLC. The findings from the study supported the FDA approval of atezolizumab on October 15, 2021, for use as adjuvant therapy following resection and platinum-based chemotherapy in patients with stage II to IIIA NSCLC whose tumors have PD-L1 expression on 1% or more of tumors cells.
Although more data are needed, early overall survival data from the interim analysis of the study demonstrated a hazard ratio of 0.77 with adjuvant atezolizumab in patients with stage II to IIIA disease and PD-L1 expression of 1% or higher, 0.99 in all randomized patients with stage II to IIIA disease, and 1.07 in the intention-to-treat population, Aggarwal concludes.
